Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Accumulated Expenses (2019 - 2025)

Biodesix's Other Accumulated Expenses history spans 7 years, with the latest figure at $992000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 54.76% year-over-year to $992000.0; the TTM value through Dec 2025 reached $992000.0, up 54.76%, while the annual FY2025 figure was $992000.0, 54.76% up from the prior year.
  • Other Accumulated Expenses reached $992000.0 in Q4 2025 per BDSX's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.6 million in Q1 2021 to a low of $294000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 80.07% in 2024, then soared 645.24% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.8 million in 2021, then decreased by 16.31% to $2.3 million in 2022, then rose by 24.06% to $2.9 million in 2023, then plummeted by 77.68% to $641000.0 in 2024, then skyrocketed by 54.76% to $992000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Other Accumulated Expenses are $992000.0 (Q4 2025), $2.0 million (Q3 2025), and $638000.0 (Q2 2025).